Adjuvants can be obtained directly from natural products in nature, or new types are sought by artificial synthesis. Glucan is a polysaccharide derived from D-glucose in nature. The researchers tested carbohydrates from plant, microbial, and synthetic sources and found glucan to be the most promising vaccine adjuvant. Glucan alone stimulates various immune responses without any side effects. CD BioGlyco provides β-glucan adjuvants development services for different vaccines. We are confident to be your indispensable assistant in adjuvant development.
β-Glucan is glucose homopolymers isolated from yeast and fungal cell walls. It has strong immunomodulatory properties without significant toxicity or negative side effects. β-Glucan adjuvants stimulate innate and adaptive immune responses through different pathways, depending on source, structure, and formulation. β-Glucan binds to C-type lectin dectin-1 and other recognition receptors, stimulates granulocytes, monocytes, macrophages, and natural killer (NK) cells, resulting in the enhancement of the body's humoral and cellular immunity. Recently, researchers have developed conjugates to enhance antigen-specific antibody responses using β-glucan as a carrier and immune activator.
Due to its antioxidant, anti-inflammatory, and immunomodulatory properties, glucan is considered the most ideal candidate for adjuvants. In a mouse model, β-glucan microparticles derived from baker's yeast significantly enhanced the phagocytic activity of mouse peritoneal macrophages, which subsequently secreted pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β). Sulfated β-glucan from Saccharomyces cerevisiae induced proliferation of chicken lymphosplenocytes and increased serum antibody and serum cytokine concentrations. Curdlan, β-glucan variant, enhanced the immunogenicity of hepatitis B vaccine and supported immune responses in a mouse model compared to aluminum adjuvant.
Fig.1 Inhibition of tumor growth by β-glucans through promoting CD4+ T cell immunomodulation and neutrophil-killing in mice. (Zou, 2019)
β-Glucan is an adjuvant as well as an effective vaccine delivery platform, and β-glucan microparticles have large antigenic payloads. CD BioGlyco has established a powerful adjuvant development platform. We offer various β-glucan adjuvant and their modified variant development services according to customers' needs. Our services include but are not limited to:
CD BioGlyco has developed an advanced Glyco™ Vaccine Development Platform, we provide customized solutions for β-glucan adjuvant development. Meanwhile, our scientists will continue to track and guide the development process to provide the best guarantee for your project. If you are interested in our β-glucan adjuvant development service, please feel free to contact us.
References:
